Pharsight

Lupkynis patents expiration

LUPKYNIS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7332472 AURINIA Cyclosporine analogue mixtures and their use as immunomodulating agents
Oct, 2024

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11622991 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(13 years from now)

US10286036 AURINIA Protocol for treatment of lupus nephritis
Dec, 2037

(13 years from now)

Lupkynis is owned by Aurinia.

Lupkynis contains Voclosporin.

Lupkynis has a total of 3 drug patents out of which 0 drug patents have expired.

Lupkynis was authorised for market use on 22 January, 2021.

Lupkynis is available in capsule;oral dosage forms.

Lupkynis can be used as treatment of patients with active lupus nephritis.

Drug patent challenges can be filed against Lupkynis from 22 January, 2025.

The generics of Lupkynis are possible to be released after 07 December, 2037.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 22, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using VOCLOSPORIN ingredient

NCE-1 date: 22 January, 2025

Market Authorisation Date: 22 January, 2021

Treatment: Treatment of patients with active lupus nephritis

Dosage: CAPSULE;ORAL

More Information on Dosage

LUPKYNIS family patents

Family Patents